Drug Profile

Research programme: antisense oligonucleotide therapeutics - RogCon U.R

Alternative Names: RCUR 313; RCUR SMP

Latest Information Update: 28 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator RogCon U.R
Developer Florey Institute of Neuroscience and Mental Health; Ionis Pharmaceuticals; RogCon U.R
Class Antiepileptic drugs; Antisense oligonucleotides; Behavioural disorder therapies
Mechanism of Action NAV1.2 voltage-gated sodium channel expression stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jan 2023 No recent reports of development identified for preclinical development in Autistic-disorder in USA
28 Jan 2023 No recent reports of development identified for preclinical development in Epilepsy in USA
01 Dec 2018 Preclinical trials in Autistic disorder in USA (unspecified route) prior to December 2018 (RogCon U.R website, December 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com